206 related articles for article (PubMed ID: 18719344)
21. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
22. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
23. Preface: Gastroenteropancreatic system and its tumors: Part 2.
Vinik AI
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):xvii-xviii. PubMed ID: 21349408
[No Abstract] [Full Text] [Related]
24. [Contemporary methods of diagnosis and treatment of neuroendocrine gastrointestinal tumors].
Kos-Kudła B; Zemczak A
Endokrynol Pol; 2006; 57(2):174-86. PubMed ID: 16773594
[TBL] [Abstract][Full Text] [Related]
25. [Polish diagnostic and therapeutic guidelines in gastroenteropancreatic neuroendocrine tumors (GEP NET)].
Kos-Kudła B;
Endokrynol Pol; 2006; 57(3):267-72. PubMed ID: 17111342
[No Abstract] [Full Text] [Related]
26. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
[TBL] [Abstract][Full Text] [Related]
27. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
29. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Oberg K; Jelic S;
Ann Oncol; 2008 May; 19 Suppl 2():ii104-5. PubMed ID: 18456741
[No Abstract] [Full Text] [Related]
31. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
de Herder WW
Eur J Endocrinol; 2014 May; 170(5):R173-83. PubMed ID: 24723670
[TBL] [Abstract][Full Text] [Related]
32. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
33. Localization of gastroenteropancreatic tumours by angiography.
Doppman JL; Jensen RT
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S163-6. PubMed ID: 10604123
[TBL] [Abstract][Full Text] [Related]
34. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
35. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
36. [Incidence, pathology and clinical course and symptoms of neuroendocrine gastrointestinal tumours].
Federspiel BH; Hansen CP; Vainer B; Hasselby JP; Bardram L; Knigge U
Ugeskr Laeger; 2010 Oct; 172(43):2946-50. PubMed ID: 21040672
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.
Sandvik OM; Søreide K; Gudlaugsson E; Kvaløy JT; Søreide JA
Br J Surg; 2016 Feb; 103(3):226-32. PubMed ID: 26511392
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
39. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
40. [Neurendocrine tumours of the appendix, colon and rectum: current surgical aspects].
Rosato L; De Tomaa G; Mondini G; Bertone P; Fornari F; Orlassino R
Chir Ital; 2007; 59(4):445-52. PubMed ID: 17966763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
